All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Orphan Drug Designation to MAb-AR20.5 in Pancreatic Cancer

August 21st 2023

The FDA has granted an orphan drug designation to the IgG1k type murine monoclonal antibody MAb-AR20.5 for the treatment of patients with pancreatic cancer.

Emerging Uses for Circulating Tumor Cell Technology

August 21st 2023

Detection of circulating tumor cells, which are released from primary or metastatic lesions into the bloodstream and are the “seeds” for distant metastatic lesions, has been of interest in cancer research and treatment because these cells can potentially provide information on cancer detection, prognosis, and likelihood of treatment response with minimally invasive methods.

Atezolizumab Plus Cabozantinib Improves PFS in Hormone Therapy–Pretreated mCRPC

August 21st 2023

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.

CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

August 21st 2023

Marios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotlights the activity and safety of CGX1321 with or without pembrolizumab in phase 1 studies, and emphasizes the need for continued investigation of CGX1321 to further validate this precision medicine approach.

Adjuvant Furmonertinib Shows Efficacy, Tolerability in EGFR+ NSCLC With High-Risk Factors

August 20th 2023

Furmonertinib had efficacy and an acceptable toxicity profile when utilized as adjuvant treatment in EGFR-mutated, stage IA2-IIIA non–small cell lung cancer with high-risk pathological factors who have undergone radical surgery

TNB-486 Elicits 91% CR Rate in Heavily Pretreated, High-Risk Follicular Lymphoma

August 19th 2023

TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy.

Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC

August 18th 2023

Patients with mismatch repair–deficient and/or microsatellite instability metastatic colorectal cancer experienced a progression-free survival benefit with longer disease control following treatment with avelumab compared with standard second-line chemotherapy.

Second-Line Axi-Cel Elicits Complete Metabolic Responses in Transplant-Ineligible LBCL

August 18th 2023

Second-line treatment with axicabtagene ciloleucel led to an investigator-assessed, 3-month complete metabolic response rate of 71.0% in patients with large B-cell lymphoma who were ineligible for autologous stem cell transplant.

Talquetamab Helps Usher in Era of Bispecific Antibodies in Relapsed/Refractory Myeloma

August 18th 2023

Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

August 18th 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies for Patients

August 18th 2023

Researchers at City of Hope were awarded $32.3 million from the CIRM to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia.

Belzutifan Improves PFS in Pretreated Advanced RCC

August 18th 2023

Treatment with belzutifan demonstrated a statistically significant and clinically meaningful improvement in progression-free survivalcompared with everolimus in patients with advanced renal cell carcinoma that has progressed on prior PD-1/PD-L1 and VEGF inhibitors, in sequence or in combination.

European Commission Approves Reduced Dosing of Teclistamab in Relapsed/Refractory Myeloma

August 18th 2023

The European Commission has approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved a complete response or better for a minimum of 6 months.

Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features

August 18th 2023

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Ociperlimab Plus Tislelizumab/Chemo Has Antitumor Activity in Stage IV Gastric/GEJ Cancers

August 18th 2023

The combination of ociperlimab, tislelizumab, and chemotherapy elicited responses in patients with stage IV gastric or gastroesophageal junction cancer, irrespective of PD-L1 expression.

Zanubrutinib Sustains Response, Safety Benefits Vs Ibrutinib in Waldenström Macroglobulinemia

August 17th 2023

Zanubrutinib demonstrated long-term efficacy with superior tolerability compared with ibrutinib for the treatment of patients with symptomatic Waldenström macroglobulinemia regardless of CXCR4 or MYD88 mutational status.

Selective Use of Neoadjuvant Chemoradiation Is a Viable Approach in Locally Advanced Rectal Cancer

August 17th 2023

Deb Schrag, MD, MPH, discusses the rationale for exploring the use of selective preoperative chemoradiation in patients with locally advanced rectal cancer, the safety and efficacy findings from the PROSPECT trial, and the importance of reviewing patient-reported outcomes during clinical trials.

Frontline Quizartinib Plus Chemotherapy Shows Curative Potential in FLT3-ITD Wild-Type AML

August 17th 2023

The addition of quizartinib to standard induction and consolidation chemotherapy with idarubicin plus cytarabine followed by maintenance therapy led to an improvement in event-free survival compared with placebo plus chemotherapy in patients with FLT3-ITD wild-type acute myeloid leukemia.

Tazemetostat Plus Lenalidomide and Rituximab Under Investigation in R/R Follicular Lymphoma

August 17th 2023

Jennifer Effie Amengual, MD, discusses unmet needs in FL that SYMPHONY-1 aims to address; the potential benefits of tazemetostat plus lenalidomide and rituximab in patients who are refractory to rituximab or who relapse within 24 months of their initial therapy; and where this regimen may fit into the relapsed/refractory FL treatment paradigm alongside investigative CAR T-cell therapies.

Jayan Nair, MD Joins Clinical Team at FCS Sarasota Downtown Location

August 17th 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist Jayan Nair, MD has joined the the Sarasota Downtown clinical team.